Earli is a BioAI therapeutics firm in Redwood City, California that programs cancer to turn against itself. Cancer cells become hyperlocal factories for potent immune therapies that are otherwise too toxic to be used systemically. Earli AI-designs synthetic genetic switches that are intravenously injected but ONLY activate in cancer cells, using non-integrating DNA in a stealth LNP. Once activated, they force the cancer cells to produce encoded proteins – T cell engagers, cytokines, agonists – that activate the immune system to kill the cancer. The hyperlocal activation avoids on-target/off-tumor effects and drives up the therapeutic index. Instead of focusing on where the drug goes, Earli changes where the drug is produced.
Who You Are
- You share our same sense of dedication, scientific passion and entrepreneurial spirit
- You work well in a fast-paced and extremely focused startup environment
- You are not only smart, but clever and constantly think outside the box
- You are able to make logical decisions in an instant when there is little time to evaluate
- You are a natural communicator and relationship builder
- You stay calm under high pressure and stress
- You have the ability to multi-task in a serious way, with an extreme attention to detail
- You become a representative of the core DNA of the company through who you are
The Position
This is a general submission form to join the Earli Talent Community. If you are interested in working at Earli but don't see a current opening that aligns with your skills and background we're always on the lookout for great people who are interested in working with us or who are interested in potential upcoming internship opportunities available in our lab.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
What We Do
Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
